THE US Food and Drug
Administration has announced
class-wide safety labelling changes
and new postmarket study
requirements for all extendedrelease
and long-acting (ER/LA)
opioid analgesics.
The updated indication states
that the opioids are indicated for
the management of pain “severe
enough to require daily, aroundthe-
clock, long-term opioid
treatment and for which alternative
treatment options are inadequate”.
The FDA is also requiring a new
boxed warning on ER/LA opioids
cautioning about neonatal opioid
withdrawal syndrome if they are
used during pregnancy.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.